Phase 3 Randomized Study of TLK286 (Telcyta) in Combination With Liposomal Doxorubicin (Doxil/Caelyx)Versus Liposomal Doxorubicin (Doxil/Caelyx) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer (ASSIST-5).

Trial Profile

Phase 3 Randomized Study of TLK286 (Telcyta) in Combination With Liposomal Doxorubicin (Doxil/Caelyx)Versus Liposomal Doxorubicin (Doxil/Caelyx) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer (ASSIST-5).

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Nov 2013

At a glance

  • Drugs Canfosfamide; Doxorubicin liposomal
  • Indications Ovarian cancer; Peritoneal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ASSIST-5
  • Most Recent Events

    • 23 Feb 2011 Primary endpoint 'Progression-free-survival' has not been met according to article in the International Journal of Gynecological Cancer.
    • 02 Jun 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 02 Jun 2009 Results were reported at ASCO 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top